SCHEMBL3104264

SCHEMBL3104264

O=C(c1csc(-c2ccncc2)n1)N1CCC(C(=O)O)(c2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.56
CNR2 P34972 1/20 0.56
KMT2A Q03164 3/20 0.45
TET3 O43151 1/20 0.45
FBXL19 Q6PCT2 1/20 0.45
CXXC5 Q7LFL8 1/20 0.45
TET1 Q8NFU7 1/20 0.45
KDM2B Q8NHM5 1/20 0.45
CXXC4 Q9H2H0 1/20 0.45
KDM2A Q9Y2K7 1/20 0.45
HTR2C P28335 4/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.43
HPGD P15428 1/20 0.43
ELOVL1 Q9BW60 1/20 0.43
MEN1 O00255 1/20 0.43
RAB9A P51151 1/20 0.43
CHEK1 O14757 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
CYP46A1 Q9Y6A2 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104600 0.89 IRAK4 (0.52) CNR1CNR2IRAK4RAB9ACHEK1
SCHEMBL3110037 0.89 ALDH1A1 (0.52) CNR1CNR2KMT2ATET3FBXL19
SCHEMBL13092191 0.84 CNR1 (0.47) CNR1CNR2IRAK4HPGDELOVL1
SCHEMBL4820548 0.78 HPGD (0.51) CNR1CNR2KMT2AHTR2CPTGDR2
SCHEMBL4820539 0.78 HPGD (0.51) CNR1CNR2KMT2AHTR2CPTGDR2
SCHEMBL29944217 0.76 HTR2C (0.63) KMT2AHTR2CPTGDR2HPGDMEN1
SCHEMBL3547467 0.76 HTR2C (0.63) KMT2AHTR2CPTGDR2HPGDMEN1
SCHEMBL3543198 0.76 HTR2C (0.63) KMT2AHTR2CPTGDR2HPGDMEN1
SCHEMBL2225857 0.76 HDAC1 (0.55) HTR2CPTGDR2CHEK1TLR7
SCHEMBL13092192 0.75 IRAK4 (0.46) CNR1CNR2IRAK4RAB9ACHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 CNR1 354/4885CNR2 428/4885KMT2A 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.